PRAXIS PRECISION MEDICINES, INC. Financials Praxis Precision Medicines, Inc.
Equities
PRAX
US74006W2070
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.8 USD | +3.63% |
|
+16.87% | +145.96% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,105 | 883.5 | 112.1 | 190.9 | 907.3 | - | - |
| Enterprise Value (EV) 1 | 2,105 | 883.5 | 112.1 | 109.6 | 764.5 | 844.2 | 907.3 |
| P/E ratio | -29.9 x | -5 x | -0.51 x | -1.19 x | -6.24 x | -5.74 x | -9.36 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 78 x | 394 x | 616 x | 11.2 x |
| EV / Revenue | - | - | - | 44.8 x | 332 x | 573 x | 11.2 x |
| EV / EBITDA | -34 x | -5.29 x | -0.52 x | -0.87 x | -6.82 x | -5.62 x | -5.05 x |
| EV / FCF | -40 x | -7.03 x | - | -0.99 x | -7.02 x | -6.55 x | -14.9 x |
| FCF Yield | -2.5% | -14.2% | - | -101% | -14.2% | -15.3% | -6.72% |
| Price to Book | - | - | - | 2.81 x | - | - | - |
| Nbr of stocks (in thousands) | 2,550 | 2,990 | 3,141 | 8,570 | 16,557 | - | - |
| Reference price 2 | 825.3 | 295.5 | 35.70 | 22.28 | 54.80 | 54.80 | 54.80 |
| Announcement Date | 3/17/21 | 2/28/22 | 2/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 2.447 | 2.3 | 1.472 | 81.27 |
| EBITDA 1 | -61.92 | -167.2 | -214.6 | -125.9 | -112.1 | -150.2 | -179.6 |
| EBIT 1 | -61.97 | -167.3 | -215 | -126.4 | -124.7 | -146.2 | -90.81 |
| Operating Margin | - | - | - | -5,164.41% | -5,420.09% | -9,929.45% | -111.73% |
| Earnings before Tax (EBT) 1 | -61.83 | -167.1 | -214 | -123.3 | -123.4 | -152.6 | -118 |
| Net income 1 | -70.32 | -167.1 | -214 | -123.3 | -123.4 | -152.6 | -118 |
| Net margin | - | - | - | -5,037.88% | -5,363.53% | -10,365.39% | -145.22% |
| EPS 2 | -27.60 | -59.10 | -69.60 | -18.69 | -8.778 | -9.542 | -5.854 |
| Free Cash Flow 1 | -52.62 | -125.6 | - | -111.2 | -108.9 | -128.9 | -61 |
| FCF margin | - | - | - | -4,543.77% | -4,736.02% | -8,751.78% | -75.05% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/17/21 | 2/28/22 | 2/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.683 | 0.781 | 0.468 | 0.515 | 2.04 | 0.04 | 0.04 | 0.04 | 0.1 |
| EBITDA 1 | -44.73 | -58.56 | -68.76 | -60.28 | -44.19 | -41.35 | -37.98 | -34.85 | -25.41 | -27.7 | -23.14 | -29.02 | -29.65 | -30.29 | - |
| EBIT 1 | -44.77 | -58.66 | -68.85 | -60.39 | -44.29 | -41.45 | -38.09 | -34.96 | -25.52 | -27.81 | -27.48 | -30.79 | -32.21 | -32.6 | -36.7 |
| Operating Margin | - | - | - | - | - | - | -5,577.01% | -4,476.31% | -5,452.14% | -5,399.22% | -1,347.08% | -76,975.5% | -80,527.5% | -81,510% | -36,695.5% |
| Earnings before Tax (EBT) 1 | -44.7 | -58.59 | -68.72 | -60.19 | -43.94 | -41.17 | -37.46 | -34.31 | -24.63 | -26.88 | -27.28 | -30.59 | -32.01 | -32.4 | -36.2 |
| Net income 1 | -44.7 | -58.58 | -68.72 | -60.19 | -43.94 | -41.17 | -37.46 | -34.31 | -24.63 | -26.88 | -27.28 | -30.59 | -32.01 | -32.4 | -36.2 |
| Net margin | - | - | - | - | - | - | -5,483.89% | -4,393.34% | -5,263.25% | -5,219.03% | -1,337.27% | -76,475.5% | -80,027.5% | -81,010% | -36,195.5% |
| EPS 2 | -15.00 | -19.50 | -22.65 | -19.80 | -14.40 | -13.05 | -10.65 | -7.350 | -2.700 | -2.970 | -2.076 | -2.186 | -2.272 | -2.278 | -2.645 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/9/22 | 2/7/23 | 5/11/23 | 8/9/23 | 11/7/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 81.3 | 143 | 63.1 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -52.6 | -126 | - | -111 | -109 | -129 | -61 |
| ROE (net income / shareholders' equity) | - | -62.1% | -131% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | 7.920 | - | - | - |
| Cash Flow per Share | - | -44.00 | -60.20 | - | - | - | - |
| Capex 1 | - | 1.05 | - | 0 | - | - | - |
| Capex / Sales | - | - | - | 0% | - | - | - |
| Announcement Date | 3/17/21 | 2/28/22 | 2/7/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
54.8
USD
Average target price
138.6
USD
Spread / Average Target
+152.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +145.96% | 907M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PRAX Stock
- Financials Praxis Precision Medicines, Inc.
